Infinite Computer Solutions net profit rises to Rs12.40 crore in December quarter

Infinite Computer Solutions reported net sales of Rs69.84 crore in the December 2010 as against Rs44.12 crore in the same period of the last fiscal

Infinite Computer Solutions (India) Ltd said its net profit for the December 2010 quarter stood at Rs12.40 crore compared to Rs11.62 crore in the corresponding quarter of last fiscal.

The company reported net sales of Rs69.84 crore in the December 2010 as against Rs44.12 crore in the same period of the last fiscal.

On Wednesday, Infinite Computer Solutions ended 1% down at Rs178.70 on the Bombay Stock Exchange, while the benchmark Sensex gained 0.38% to 18,090.62 points.

User

Greenply Industries net profit declines to Rs7.19 crore in December quarter

Greenply Industries reported net sales of Rs316.54 crore in the December 2010 as against Rs218.52 crore in the same period of the last fiscal

Greenply Industries Ltd said its net profit for the December 2010 quarter stood at Rs7.19 crore compared to Rs13.93 crore posted in the corresponding quarter of last fiscal. This was primarily due to losses sustained at the new MDF and laminate units at Pantnagar, Uttarakhand and Nalagarh, Himachal Pradesh, amounting to Rs12.11 crore on account of low capacity utilisations and product-mix.

The company reported net sales of Rs316.54 crore in the December 2010, registering a growth of 44.86% as against Rs218.52 crore in the same period of the last fiscal.

On Wednesday, Greenply Industries ended 3.28% up at Rs185.95 on the Bombay Stock Exchange, while the benchmark Sensex gained 0.38% to 18,090.62 points.
 

User

Venus Remedies gets MHRA approval for anti-cancer drug

Venus Remedies stands amongst the first few to receive the market authorisation for Gemcitabine

Pharma company, Venus Remedies Ltd has received authorisation from Medicine and Healthcare Regulatory Agency (MHRA), UK to sell Gemcitabine, one of the key products for the treatment of cancer.

Pawan Chaudhary, CMD, Venus Remedies, said, "Venus is all set to capture substantial market share by entering the highly lucrative market of Europe as it stands amongst the first few to receive the market authorisation for Gemcitabine." Gemcitabine is a $1.5 billion drug world wide with more than 30% market share from Europe. Gemcitabine is used in the treatment of a variety of cancerous diseases including the cancer of lungs, pancreas, bladder and breast. The product is available in the strength of 200mg and 1000mg. Both strengths of Venus dossier have been approved by UK MHRA authorities.

Venus will produce Gemcitabine from its Baddi facility in India and planned to launch the product in UK and Germany along with other EU countries by second quarter of 2011.

On Wednesday, Venus Remedies ended 3.22% up at Rs223 on the Bombay Stock Exchange, while the benchmark Sensex gained 0.38% to 18,090.62 points.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)